Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of SHR-A1811 versus pyrotinib + capecitabine in HER2-positive metastatic breast cancer
CTR20221474Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan, pyrotinib, capecitabine in breast cancer, sponsored by Hengrui Therapeutics. Started Aug 2022; status: active.
02
Drugs
trastuzumab rezetecanpyrotinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221474.